Anavex Life Sciences' Loss Widens on Higher Costs

Dow Jones

Dec 23, 2024

By Dean Seal

Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting.

The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago.

Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share.

Overheads and R&D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate.

Shares rose 9.3% to $9.43 in premarket trading.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 23, 2024 07:41 ET (12:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2493754807"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493754807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493754807?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493754807","market":"sg","top_or_hot":-1,"title":"Anavex Life Sciences' Loss Widens on Higher Costs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago. \n</p>\n<p>\n  Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share. \n</p>\n<p>\n  Overheads and R&amp;D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate. \n</p>\n<p>\n  Shares rose 9.3% to $9.43 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2024 07:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anavex Life Sciences' Loss Widens on Higher Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnavex Life Sciences' Loss Widens on Higher Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-23 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago. \n</p>\n<p>\n  Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share. \n</p>\n<p>\n  Overheads and R&amp;D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate. \n</p>\n<p>\n  Shares rose 9.3% to $9.43 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2024 07:41 ET (12:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2493754807","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493754807","pubTimestamp":1734957660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting.The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago.Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share.Overheads and R&D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate.Shares rose 9.3% to $9.43 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp.","BK4139":"生物科技"},"translate_title":"Anavex Life Sciences因成本上升而亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":1},"content_text":"By Dean Seal \n\n\n \n\n\n  Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting. \n\n\n  The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago. \n\n\n  Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share. \n\n\n  Overheads and R&D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate. \n\n\n  Shares rose 9.3% to $9.43 in premarket trading. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 07:41 ET (12:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}